Join 60 Degrees Pharmaceuticals' Live Investor Webinar: Advancing Tafenoquine for Babesiosis While Expanding ARAKODA(R) Commercialization
Key Highlights
- ➤60 Degrees Pharmaceuticals (SXTP) will host a November 10 investor webinar on tafenoquine programs.
- ➤Three relapsing babesiosis patients were cured after tafenoquine treatment in an expanded-access study.
- ➤Babesiosis trial reached 24-patient enrollment required for interim analysis.
- ➤Company estimates up to 380,000 annual U.S. patients and $245 million peak annual sales.
- ➤ARAKODA commercialization expands through sales capacity, digital marketing, GoodRx, and Runway Health.
Expert Statements
Geoff Dow, Chairman and CEO of 60 Degrees Pharmaceuticals
“The presentation will focus on the Company’s FDA-approved antimalarial ARAKODA® (tafenoquine), its commercial expansion initiatives, and the advancement of tafenoquine for babesiosis, a tick-borne infection for which there is currently no FDA-approved treatment specifically for the disease.”
ORLANDO, FL / ACCESS Newswire / November 4, 2026 / RedChip Companies will host an investor webinar on Tuesday, November 10, 2026, at 4:15 p.m. ET with 60 Degrees Pharmaceuticals, Inc. (Nasdaq:SXTP).
The exclusive event will feature Geoff Dow, Chairman and CEO, who will provide an overview of 60 Degrees Pharmaceuticals' strategy to develop and commercialize therapies for vector-borne diseases. The presentation will focus on the Company's FDA-approved antimalarial ARAKODA(®) (tafenoquine), its commercial expansion initiatives, and the advancement of tafenoquine for babesiosis, a tick-borne infection for which there is currently no FDA-approved treatment specifically for the disease.
Get started
Create a free account to read the full story.
